Medical isotope developer Advanced Medical Isotope has changed its name to Vivos to reflect the firm's current focus on skin cancer treatments with its RadioGel yttrium-90 brachytherapy device.
After obtaining regulatory approval for the skin cancer indication, Vivos intends to grow over time by expanding the number of cancer types treated by RadioGel, said CEO Mike Korenko, PhD, in a statement. In addition, Korenko said that Vivos will also consider noncancer applications, such as treating bone infections that currently lead to amputation.
Effective January 2, the company's shares now trade on the OTC Markets under the RDGL symbol. Vivos said it anticipates qualifying the common stock for quotation on the OTCQB exchange in the near term, with the longer-term goal of listing on a national exchange.
